GLP-1 Access in Canada: Options, Costs & Clinical Considerations

Last reviewed: June 2, 2026

Last updated: June 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, GLP-1 receptor agonists are available in Canada, but access varies significantly by province, medication type, and insurance coverage. Branded options like Ozempic and Mounjaro are available through prescriptions, while compounded formulations offer additional pathways. Understanding these options requires clarity on cost, approval timelines, and clinical fit for individual patients.

For Canadian patients considering GLP-1 therapy, access is only the first decision. Equally important is determining which GLP-1 approach aligns with individual metabolic and genetic predispositions. A precision-medicine framework—informed by peptide pathway genetics and clinical history—can support more targeted, personalized treatment planning with your healthcare provider.

GLP-1 Medications Currently Available in Canada

Semaglutide (Ozempic for diabetes, Wegovy for weight management) and tirzepatide (Mounjaro for diabetes) are Health Canada-approved and available via prescription. Both require individual authorization in most provinces. Saxenda (liraglutide) remains available but is less commonly prescribed for weight management in Canada due to efficacy and cost considerations compared to newer agents.

Compounded semaglutide and tirzepatide are also accessible through licensed Canadian 503A compounding pharmacies, offering an additional route for patients seeking alternatives to branded medications. These formulations are prepared by pharmacists under strict quality standards, though they are not Health Canada-approved branded products.

Canadian Access Pathways: Provincial Coverage, Timelines, and Costs

Access to GLP-1 medications in Canada depends heavily on provincial health insurance, private coverage, and individual clinical criteria. Some provinces cover semaglutide or tirzepatide for diabetes under specific circumstances, while weight-management indications often require private payment or specialized insurance plans. Understanding your province's formulary status and approval process is essential before initiating treatment.

Access Pathway	Coverage Model	Typical Timeline	Cost Range (CAD/month)
Provincial Health Insurance (Diabetes)	Limited to specific provinces and criteria	2–8 weeks after approval	$0–150 (covered); varies by province
Private Insurance	Depends on plan; often requires prior auth	1–3 weeks post-approval	$100–400 out-of-pocket or co-pay
Out-of-Pocket (Branded)	Patient pays full cost	1–2 weeks post-prescription	$250–500+ per month
Compounded via Licensed Pharmacy	Patient pays or insurance covers selective pharmacy	3–7 days after provider approval	$149–289 per month (PlexusDx range)

Branded Versus Compounded: Clinical and Practical Distinctions

Branded GLP-1 medications (Ozempic, Wegovy, Mounjaro) are manufactured by pharmaceutical companies, undergo rigorous regulatory approval, and include extensive clinical trial data. Compounded GLP-1 medications are prepared by licensed 503A compounding pharmacies using pharmaceutical-grade active ingredients, adhering to strict quality standards but without branded clinical trial portfolios.

Both pathways can be medically appropriate depending on patient access, cost, provider preference, and clinical context. Branded medications offer established dosing protocols and extensive safety databases. Compounded formulations may offer cost advantages and faster procurement in some provinces. A qualified provider should weigh clinical evidence, individual patient factors, and availability when recommending either option.

Genetic Predispositions in GLP-1 Pathways: How Personalization Supports Canadian Treatment Selection

Emerging evidence suggests that genetic variants in GLP-1 receptor (GLP1R rs6923761) and glucose-dependent insulinotropic polypeptide receptor (GIPR rs1800437) pathways may influence individual responses to GLP-1 therapy. These predispositions are distinct from pharmacogenetic interactions and reflect baseline signaling capacity in metabolic pathways that GLP-1 agents target.

Understanding an individual's genetic predispositions in these peptide pathways—through tools like the Precision Peptide Genetic Test—may help provide context for treatment selection and dose requirements. A provider can use this information alongside clinical history, metabolic markers, and comorbidities to tailor GLP-1 choice and management strategy. Genetic insights should always be interpreted with a qualified healthcare provider and never used in isolation.

Safety Considerations and Provider Guidance for Canadian Patients

GLP-1 therapy carries established side effects—nausea, vomiting, gastrointestinal symptoms, and rare pancreatitis reports—that require medical supervision. Patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use GLP-1 agents. Dehydration risk and medication interactions must be reviewed with a healthcare provider before starting treatment.

Canadian patients should work with a qualified physician or nurse practitioner to assess eligibility, establish baseline health markers, and monitor response over time. Regular follow-up is essential to manage side effects, adjust dosing, and evaluate therapeutic benefit. If compounded formulations are chosen, ensure they are sourced from licensed, reputable 503A compounding pharmacies that maintain quality and safety certifications.

How PlexusDx Supports a More Personalized Approach

PlexusDx connects Canadian patients with compounded GLP-1 formulations prepared by licensed 503A pharmacies, offering a direct-to-provider pathway that can reduce wait times compared to some provincial approval processes. Compounded semaglutide injection starts at $149/month and oral semaglutide at $249/month, with tirzepatide options also available. Pricing remains flat across commitment tiers—your dose may increase, but your cost won't.

The Precision Peptide Genetic Test ($99 after the first month of treatment) reveals predispositions in GLP1R, GIPR, FTO, and MC4R genetic variants that may influence peptide pathway sensitivity and metabolic response. This test does not predict exact medication response or guarantee outcomes; instead, it may help provide context for why an individual might respond differently to GLP-1 therapy and can support more informed dosing and medication selection conversations.

For Canadian patients exploring GLP-1 options, genetic insights combined with clinical evaluation can support a more personalized conversation with your healthcare provider about which GLP-1 formulation, dose pathway, and monitoring strategy may be most appropriate for your individual situation.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.